ROHIDAS PATIL: Open Payments
NPI 1871601989 · DECATUR, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,086 in 47 payments from 10 companies in 2025. Trend: 2023 $1,780 · 2024 $1,447 · 2025 $1,086
Food & beverage: $1,086
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $328 |
| Alkermes, Inc. | 9 | $226 |
| Neurocrine BioSciences, Inc. | 8 | $200 |
| E.R. Squibb & Sons, L.L.C. | 5 | $110 |
| Janssen Pharmaceuticals, Inc | 5 | $107 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Lundbeck LLC | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Corium, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
Products named: ARISTADA, INGREZZA, REXULTI, ABILIFY ASIMTUFII, COBENFY, INVEGA SUSTENNA, Sunosi, ABILIFY MAINTENA.
Industry payments across IL — which companies pay providers there.
